½ÃÀ庸°í¼­
»óǰÄÚµå
1306994

¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)

Global Bronchodilators Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

±â°üÁö È®ÀåÁ¦ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 238¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 350¾ï 5,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2023-2030³âÀÇ Á¶»ç ±â°£ µ¿¾È 4.92%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â°üÁö È®ÀåÁ¦´Â ÆóÀÇ °ø±â Åë·Î¸¦ ³ÐÇô ¼û½¬±â ½±°Ô ÇÏ´Â ¾àÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) ¹× È£Èí°ï¶õÀ» À¯¹ßÇÏ´Â ±âŸ È£Èí±â ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ¾àµéÀº ÆóÀÇ ±âµµ¸¦ µÑ·¯½Î°í ÀÖ´Â ±ÙÀ°À» À̿ϽÃÄÑ ±âµµ¸¦ ³ÐÇô °ø±â È帧À» °³¼±ÇÏ´Â ÀÛ¿ëÀ» ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

±â°üÁö È®ÀåÁ¦ ½ÃÀåÀº õ½Ä, COPD, ±â°üÁö¿°°ú °°Àº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀÇ ¼¼°è À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿À²ÀûÀÎ ¾à¹°¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. È£Èí±â °Ç°­ À¯ÁöÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ÀÌ ½ÃÀåÀ» À̲ô´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. »ç¶÷µéÀº È£Èí±â Áúȯ°ú °ü·ÃµÈ À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±â°üÁö È®ÀåÁ¦ »ç¿ëÀ» Æ÷ÇÔÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀ» ¿¹¹æÇÏ°í °ü¸®Çϱâ À§ÇÑ Á¶Ä¡¸¦ ÃëÇÏ°Ô µÇ¾ú½À´Ï´Ù. »õ·Î¿î ¾à¹° Àü´Þ ±â¼úÀÇ °³¹ßµµ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Á¤·® ÈíÀÔ±â, °ÇÁ¶ ºÐ¸» ÈíÀÔ±â, ºÐ¹«±â¿Í °°Àº ÈíÀÔ ÀåÄ¡°¡ ´õ¿í ¹ßÀüÇÏ¿© ȯÀÚµéÀÌ º¸´Ù Æí¸®ÇÏ°í ½±°Ô ¾à¹°À» Åõ¿©ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼¼°èÀûÀ¸·Î ³ëÀÎ Àα¸°¡ Áõ°¡Çϸ鼭 ±â°üÁö È®ÀåÁ¦ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ³ëÀεéÀº È£Èí±â Áúȯ¿¡ °É¸®±â ½¬¿ì¸ç, Áõ»óÀ» °ü¸®Çϱâ À§ÇØ ±â°üÁö È®ÀåÁ¦·Î Àå±âÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. Á¦¾à»çµéÀº º¸´Ù È¿°úÀûÀÎ ½Å¾àÀ» °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ°í »õ·Î¿î È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â°üÁö È®ÀåÁ¦ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ :

±â°üÁö È®ÀåÁ¦ ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡°¡ ÇâÈÄ ±âȸ¿Í ÇÔ²² °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

¾à¹° À¯Çüº°

  • ¥â ¾Æµå·¹³¯¸°¼º ±â°üÁö È®ÀåÁ¦
  • ÀÜÆ¾ À¯µµÃ¼
  • Ç×Äݸ°¼º ±â°üÁö È®ÀåÁ¦

Åõ¿©°æ·Îº°

  • °æ±¸
  • ºñ°­(ÈíÀÔ °¡´É)
  • ÁÖ»çÁ¦

Áúº´º°

  • õ½Ä
  • ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)
  • ±âŸ

Áö¿ªº° ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå ±â°üÁö È®ÀåÁ¦ - ¾÷°è ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • PorterÀÇ Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀûÀÎ ±¸¸ÅÀÚ ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå ºÐ¼® : ¾àÁ¦ Ŭ·¡½ºº°

  • ¾àÁ¦ Ŭ·¡½ºº° °³¿ä
  • °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¾àÁ¦ Ŭ·¡½ºº° ºÐ¼®
  • ¥â ¾Æµå·¹³¯¸°¼º ±â°üÁö È®ÀåÁ¦
  • ÀÜÆ¾ À¯µµÃ¼
  • Ç×Äݸ°¼º ±â°üÁö È®ÀåÁ¦

Á¦6Àå ¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

  • Åõ¿© °æ·Îº° °³¿ä
  • °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Åõ¿© °æ·Îº° ºÐ¼®
  • °æ±¸
  • ºñ°­(ÈíÀÔ °¡´É)
  • ÁÖ»çÁ¦

Á¦7Àå ¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå ºÐ¼® : Áúȯº°

  • Áúȯº° °³¿ä
  • °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Áúȯº° ºÐ¼®
  • õ½Ä
  • ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ÇÕÁß±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â°üÁö È®ÀåÁ¦ ±â¾÷ÀÇ °æÀï ±¸µµ

  • ±â°üÁö È®ÀåÁ¦ ½ÃÀå °æÀï
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ
  • ÀμöÇÕº´(M&A)
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • F. Hoffmann-La Roche Ltd
  • GSK plc.
  • Johnson &Johnson Services Inc.
  • AstraZeneca
  • Siemens Healthcare GmbH
  • Abbott
  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific
  • Quest Diagnostics Incorporated.
  • FOUNDATION MEDICINE INC.

Âü°í - ±â¾÷ ÇÁ·ÎÆÄÀϸµ¿¡¼­ À繫 ¼¼ºÎ Á¤º¸ ¹× ÃÖ±Ù °³¹ß ÇöȲÀº ÀÌ¿ë °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª ºñ°ø°³ ȸ»çÀÇ °æ¿ì ´Ù·çÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

LSH 23.08.24

The global demand for Bronchodilator Market is presumed to reach the market size of nearly USD 35.05 BN by 2030 from USD 23.87 BN in 2022 with a CAGR of 4.92% under the study period 2023 - 2030.

A bronchodilator is a medication that helps to open up or dilate the air passages in the lungs, making it easier to breathe. They are typically used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders that cause difficulty breathing. These medicines work by relaxing the muscles that surround the airways in the lungs, which allows the air passages to widen and improve airflow.

Market Dynamics:

The bronchodilator market is experiencing significant growth due to the escalating prevalence of respiratory disorders like asthma, COPD, and bronchitis. With the global incidence of these conditions on the rise, the demand for efficient medications is also increasing. The growing awareness about the importance of maintaining good respiratory health is another factor driving this market. People are becoming more aware of the risks associated with respiratory disorders and are taking steps to prevent and manage these conditions, which includes the use of bronchodilator medications. The development of new drug delivery technologies is also driving the market. Inhalation devices such as metered-dose inhalers, dry powder inhalers, and nebulizers are becoming more advanced, making it more convenient and easy for patients to administer these medications. The global geriatric population is increasing, which is driving the demand for bronchodilator medications. The elderly are more susceptible to respiratory disorders and often require long-term treatment with bronchodilators to manage their symptoms. Pharmaceutical companies are investing heavily in research and development to develop new and more effective medications. This is driving innovation in the field and leading to the development of new effective treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of bronchodilator. The growth and trends of bronchodilator industry provide a holistic approach to this study.

Market Segmentation:

This section of the bronchodilator market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Beta-Adrenergic Bronchodilators
  • Xanthine Derivatives
  • Anticholinergic Bronchodilators

By Route Of Administration

  • Oral
  • Nasal (Inhalable)
  • Injectable

By Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Bronchodilator market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the bronchodilator market include F. Hoffmann-La Roche Ltd, GSK plc., Johnson & Johnson Services, Inc., AstraZeneca, Siemens Healthcare GmbH, Abbott, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Quest Diagnostics Incorporated., FOUNDATION MEDICINE, INC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . BRONCHODILATOR - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Disease
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BRONCHODILATOR MARKET ANALYSIS BY DRUG CLASS

  • 5.1 Overview by Drug Class
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Drug Class
  • 5.4 Beta-Adrenergic Bronchodilators Historic and Forecast Sales by Regions
  • 5.5 Xanthine Derivatives Historic and Forecast Sales by Regions
  • 5.6 Anticholinergic Bronchodilators Historic and Forecast Sales by Regions

6 . GLOBAL BRONCHODILATOR MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1 Overview by Route Of Administration
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Route Of Administration
  • 6.4 Oral Historic and Forecast Sales by Regions
  • 6.5 Nasal (Inhalable) Historic and Forecast Sales by Regions
  • 6.6 Injectable Historic and Forecast Sales by Regions

7 . GLOBAL BRONCHODILATOR MARKET ANALYSIS BY DISEASE

  • 7.1 Overview by Disease
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Disease
  • 7.4 Asthma Historic and Forecast Sales by Regions
  • 7.5 Chronic Obstructive Pulmonary Disease (COPD) Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL BRONCHODILATOR MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BRONCHODILATOR COMPANIES

  • 9.1. Bronchodilator Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF BRONCHODILATOR INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. F. Hoffmann-La Roche Ltd
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. GSK plc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Johnson & Johnson Services Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. AstraZeneca
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Siemens Healthcare GmbH
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Abbott
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Bio-Rad Laboratories Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Thermo Fisher Scientific
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Quest Diagnostics Incorporated.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. FOUNDATION MEDICINE INC.
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦